Literature DB >> 19857196

Hypercalcemia due to Graves' disease in a patient with thyroid hemiagenesis.

Levent Kebapçilar1, Bariş Akinci, Tevfik Demir, Firat Bayraktar, Sena Yeşil.   

Abstract

Thyroid hemiagenesis is a rare anomaly due to failure of development of one thyroid lobe during embryological life. A lot of thyroid disorders may accompany thyroid hemiagenesis. In this report, we present a case of thyroid hemiagenesis, who had moderate hypercalcemia due to Graves' disease. A 43-year-old woman presented with weight loss of more than 5 kg within one month, heat intolerance, and increased sweating. For the past month, she had been troubled by intermittent symptoms of vomiting, thirst, and constipation. On examination, she had tachycardia with no signs of dehydration. Pulse rate was 110 per minute. She had fine tremor, proximal muscle weakness, and asymmetric smooth goiter and hyperplasia in the right thyroid gland. Thyroid function tests confirmed the diagnosis of hyperthyroidism. Although hypercalcemia may be detected in patients with thyrotoxicosis, to the best of our knowledge, this is the first case report of thyroid hemiagenesis accompanying hypercalcemia due to thyrotoxicosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19857196

Source DB:  PubMed          Journal:  Kulak Burun Bogaz Ihtis Derg        ISSN: 1300-7475


  3 in total

1.  THYROID HEMIAGENESIS ASSOCIATED WITH GRAVES' DISEASE: A CASE REPORT AND REVIEW OF THE LITERATURE.

Authors:  G B Cansu; B Taşkıran; T Bahçeci
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Jul-Sep       Impact factor: 0.877

Review 2.  Thyroid Hemiagenesis: Narrative Review and Clinical Implications.

Authors:  Omotara Kafayat Lesi; Ankur Thapar; Nikhil Nanjappa Ballanamada Appaiah; Muhammad Rafaih Iqbal; Shashi Kumar; Dale Maharaj; Abdalla Saad Abdalla Al-Zawi; Shiva Dindyal
Journal:  Cureus       Date:  2022-02-20

3.  Does TSH Trigger the Anti-thyroid Autoimmune Processes? Observation on a Large Cohort of Naive Patients with Thyroid Hemiagenesis.

Authors:  Ewelina Szczepanek-Parulska; Ariadna Zybek-Kocik; Kosma Woliński; Barbara Czarnocka; Marek Ruchała
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2016-03-14       Impact factor: 4.291

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.